ALS-linked protein disulfide isomerase variants cause motor dysfunction

Disturbance of endoplasmic reticulum (ER) proteostasis is a common feature of amyotrophic lateral sclerosis (ALS). Protein disulfide isomerases (PDIs) are ER foldases identified as possible ALS biomarkers, as well as neuroprotective factors. However, no functional studies have addressed their impact...

Full description

Saved in:
Bibliographic Details
Published inThe EMBO journal Vol. 35; no. 8; pp. 845 - 865
Main Authors Woehlbier, Ute, Colombo, Alicia, Saaranen, Mirva J, Pérez, Viviana, Ojeda, Jorge, Bustos, Fernando J, Andreu, Catherine I, Torres, Mauricio, Valenzuela, Vicente, Medinas, Danilo B, Rozas, Pablo, Vidal, Rene L, Lopez-Gonzalez, Rodrigo, Salameh, Johnny, Fernandez-Collemann, Sara, Muñoz, Natalia, Matus, Soledad, Armisen, Ricardo, Sagredo, Alfredo, Palma, Karina, Irrazabal, Thergiory, Almeida, Sandra, Gonzalez-Perez, Paloma, Campero, Mario, Gao, Fen-Biao, Henny, Pablo, van Zundert, Brigitte, Ruddock, Lloyd W, Concha, Miguel L, Henriquez, Juan P, Brown, Robert H, Hetz, Claudio
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 15.04.2016
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disturbance of endoplasmic reticulum (ER) proteostasis is a common feature of amyotrophic lateral sclerosis (ALS). Protein disulfide isomerases (PDIs) are ER foldases identified as possible ALS biomarkers, as well as neuroprotective factors. However, no functional studies have addressed their impact on the disease process. Here, we functionally characterized four ALS‐linked mutations recently identified in two major PDI genes, PDIA1 and PDIA3/ERp57. Phenotypic screening in zebrafish revealed that the expression of these PDI variants induce motor defects associated with a disruption of motoneuron connectivity. Similarly, the expression of mutant PDIs impaired dendritic outgrowth in motoneuron cell culture models. Cellular and biochemical studies identified distinct molecular defects underlying the pathogenicity of these PDI mutants. Finally, targeting ERp57 in the nervous system led to severe motor dysfunction in mice associated with a loss of neuromuscular synapses. This study identifies ER proteostasis imbalance as a risk factor for ALS, driving initial stages of the disease. Synopsis The degeneration of motoneurons in ALS is associated with a chronic endoplasmic reticulum (ER) stress response. Here we report the consequences of mutations of two major ER foldases in ALS known as PDIA1 and ERp57. Expression of these ALS‐linked mutants trigger some cardinal features of ALS, including the disruption of motoneuron connectivity and function, highlighting ER proteostasis imbalance as a driver of the initial stages of the disease. ALS‐linked mutations in PDIA1 and ERp57 adversely affect PDI structure and function. PDI mutants cause abnormal motoneuron morphology and functionality. Targeting of ERp57 in the CNS results in premature death and impaired motor control. ERp57 deficiency causes alterations of neuromuscular junctions. Disease phenotypes associated with expression of mutant PDIA1 and ERp57 show how impaired ER proteostasis can drive initial stages of amyotrophic lateral sclerosis pathology.
Bibliography:ark:/67375/WNG-7GQB3JSW-J
Muscular Dystrophy Association - No. 382453
ALS Therapy Alliance - No. 2014-F-059
Biocenter Oulu, Finland
ArticleID:EMBJ201592224
COPEC-UC Foundation
Alfonso Martin Escudero Foundation (Madrid)
NIH/NINDS - No. 1R01NS050557
CONICYT Doctoral fellowship
Michael J Fox Foundation for Parkinson's Research
istex:B528C6D1D2D30B6C078ECD1018150DFC4C2A4572
ALSRP Therapeutic Idea Award - No. AL150111
P2ALS
FONDAP - No. 15150012
MINREB Millennium Nucleus - No. RC120003
Millennium Institute - No. P09-015-F; No. CONICYT-USA2013-0003
ALS Family Charitable Foundation
Pierre L. de Bourgknecht ALS Research Foundation
Ring Initiative - No. ACT1109; No. ACT1114
Project ALS
Angel Fund
Frick Foundation
FONDECYT - No. 3110067; No. 1150743; No. 3130351; No. 11150579; No. 1150608; No. 1140549; No. 11090324; No. 1140301; No. DRI-USA 2013-0030; No. 1130321; No. 1110433
NIH - No. NS057553-07
AppendixExpanded View Figures PDFVideo EV1Video EV2Video EV3Video EV4Video EV5Video EV6Video EV7Source Data for Expanded View and AppendixReview Process FileSource Data for Figure 1BSource Data for Figure 2ASource Data for Figure 3A,ISource Data for Figure 4A,F,GSource Data for Figure 5ASource Data for Figure 7ASource Data for Figure 8A
Howard Hughes Medical Institute - No. HHMI INTNL 55005940
FONDEF - No. D11I1007
CONICYT - No. 24110099
Office of Naval Research-Global (ONR-G) - No. N62909-16-1-2003
Al-Athel ALS Research Foundation
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0261-4189
1460-2075
1460-2075
DOI:10.15252/embj.201592224